SCHEMBL1546083

SCHEMBL1546083

O=S(=O)(CCCF)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 1/20 0.52
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
HDAC1 Q13547 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
HSD11B1 P28845 5/20 0.48
MMP3 P08254 2/20 0.47
MMP8 P22894 2/20 0.47
MMP13 P45452 2/20 0.47
MMP1 P03956 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL778246 0.86 PSIP1 (0.56) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL576918 0.86 KEAP1 (0.63) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL10629823 0.86 PSIP1 (0.61) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL10626503 0.84 HDAC1 (0.65) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL4409970 0.83 PSIP1 (0.52) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL777601 0.81 PSIP1 (0.67) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL17266530 0.81 KEAP1 (0.54) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL8972497 0.80 PSIP1 (0.54) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL7295821 0.80 PSIP1 (0.54) PSIP1KEAP1NFE2L2HDAC1HDAC8
SCHEMBL3576166 0.79 PLCG1 (0.57) HSD11B1ALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311802-A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor Abbott GmbH & Co. KG (DE) 2011-04-20 EP disclosed
EP-2311803-A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor Abbott GmbH & Co. KG (DE) 2011-04-20 EP disclosed